Juntendo Medical Journal
Online ISSN : 2188-2134
Print ISSN : 0022-6769
ISSN-L : 0022-6769
Japan-Indonesia Collaborative Study of Imidapril on Antiproteinuric Effect in Hypertensive Patients with Chronic Kidney Disease (CKD)
TOSHINAO TSUGEWIGUNO PRODJOSUDJADIMOHAMMAD YOGIANTOROATSUSHI KURUSUISAO OHSAWANORTYOSHI KOBAYASHIYOSHIO SHIMIZUSUHARDJONODHARMEIZARGINOVA NAINGGOLANAIDA LIDYAPRANAWACHANDRA MOHANIDJOKO SANTOSOWIDODORIZANIANSYAHSATOSHI HORIKOSHIYASUHIKO TOMINO
Author information
JOURNALS FREE ACCESS

2010 Volume 56 Issue 2 Pages 100-106

Details
Abstract

Background: Chronic kidney disease (CKD) is a comprehensive disease concept that includes chronic glomerulonephritis such as IgA nephropathy or lupus nephritis, diabetic nephropathy and hypertensive nephrosclerosis. CKD is a risk factor for end stage kidney disease (ESKD) and cardiovascular diseases (CVD). It is considered that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) induce a marked renoprotective effect in patients with CKD. The purpose of the present Japan-Indonesia collaborative study was to evaluate the antiproteinuric effect of imidapril, one of the ACEIs, in hypertensive patients with CKD. Methods: Twenty three hypertensive CKD patients were treated with imidapril and a calcium channel blocker (CCB). Imidapril was added for patients who had been treated with a CCB such as diltiazem at the start of this study. When blood pressure (BP) did not reach the target level (<130/85 mmHg), imidapril dosage was increased to 10 mg/day and administered for 12 months. Alternatively, patients were treated with 5-10 mg/day of imidapril. Results: In the imidapril + CCB combination therapy, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were significantly reduced, both at 6 months and at the end of the clinical study. Only DBP reached values below the target level. Urinary albumin excretion (UAE) levels were markedly decreased at 6 and 12 months when compared with the baseline values (0.45 ± 0.54g/g·Cr indicating typical overt proteinuria) and these decreases at both time points were significant. The UAE levels at both 6 and 12 months complied with the diagnostic criteria for microalbuminuria (< 0.299 g/g·Cr). Conclusion: In this collaborative study, a combination of imidapril and a CCB, such as diltiazem, significantly reduced BP, and reduced UAE, suggesting strict BP control may induce an efficient decrease in UAE. It appears that imidapril-based therapy has renoprotective effects in hypertensive patients with CKD.

Information related to the author
© 2010 The Juntendo Medical Society
Previous article Next article
feedback
Top